成功闯关美国5个月后,礼来制药的阿尔茨海默病(AD)新药在中国获批。
KisunlaTM (donanemab-azbt) , pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...